Publications for Michael B. Clearfield michael.clearfield@tu.edu

Preiss, D., Campbell, R. T., Murray, H. M., Ford, I., Packard, C. J., Sattar, N., . . . Clearfield, M. B. (2015). The effect of statin therapy on heart failure events: A collaborative meta-analysis of unpublished data from major randomized trials. European Heart Journal, 36, 1536-1546. doi:10.1093/eurheartj/ehv072

Boekholdt, S. M., Hovingh, G. K., Mora, S., Arsenault, B. J., Amarenco, P., Pedersen, T. R., . . . Clearfield, M. B. (2014). Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: A meta-analysis of statin trials. Journal of the American College of Cardiology, 64(5), 485-494. doi:10.1016/j.jacc.2014.02.615

Clearfield, M. B., Pearce, M., Nibbe, Y., Crotty, D., & Wagner, A. (2014). The "new deadly quartet" for cardiovascular disease in the 21st century: Obesity, metabolic syndrome, inflammation and climate change: How does statin therapy fit into this equation? Current Atherosclerosis Reports, 16(1) [Article 380]. doi:10.1007/s11883-013-0380-2

Boekholdt, S. M., Arsenault, B. J., Hovingh, G. K., Mora, S., Pedersen, T. R., LaRosa, J. C., . . . Clearfield, M. (2013). Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: A meta-analysis. Circulation, 128(14), 1504-1512.  doi:10.1161/CIRCULATIONAHA.113.002670

Everett, B. M., Pradhan, A. D., Solomon, D. H., Paynter, N., Macfadyen, J., Zaharris, E., . . . Clearfield, M. (2013). Rationale and design of the cardiovascular inflammation reduction trial: A test of the inflammatory hypothesis of atherothrombosis. American Heart Journal, 166(2), 199–207.  doi:10.1016/j.ahj.2013.03.018

Rehfield, P., Kopes-Kerr, C., & Clearfield, M. (2013). The evolution or revolution of statin therapy in primary prevention: Where do we go from here? Current Atherosclerosis Reports, 15(2), 298.  doi:10.1007/s11883-012-0298-0

Truong, T. T., & Clearfield, M. (2013). Acute coronary syndromes in patients without elevated low-density lipoprotein (LDL) cholesterol not predicted by serum phytosterols. Journal of the American Osteopathic Association, 113(8), e14.

Boekholdt, S. M., Arsenault, B. J., Mora, S., Pedersen, T. R., LaRosa, J. C., Nestel, P. J., . . . Clearfield, M. B. (2012). Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: A meta-analysis. JAMA, 307(12), 1302-1309. doi:10.1001/jama.2012.366

Clearfield, M. B. [Contributor for Cholesterol Treatment Trialists' (CTT) Collaboration]. (2012). Lack of effect of lowering LDL cholesterol on cancer: Meta-analysis of individual data from 175,000 people in 27 randomised trials of statin. PLos One, 71(1) [Article e29849]. doi:10.1371/journal.pone.0029849

Clearfield, M. B. [Contributor for Cholesterol Treatment Trialists' (CTT) Collaboration]. (2012). The effects of lowering LDL-C with statin therapy in people at low risk of vascular disease: A meta-analysis of individual data from 27 randomized trials. The Lancet, 380(9841), 581-590. PMCID: PMC3437972

Clearfield, M. B. (2011, April). Cardiovascular benefits of aggressive cholesterol-lowering therapy. Journal of the American Osteopathic Association, 111(4 Suppl. 3), i-eS2.

Clearfield, M. B. (2011). Combination lipid therapy in type 2 diabetes. Current Atherosclerosis Reports, 13(1), 1-3. doi:10.1007/s11883-010-0139-y

Clearfield, M. B. (2011). Statins in combination: From ARBITER-6 HALTS to ACCORD. What works? Current Atherosclerosis Reports, 13(1), 4-8. doi:10.1007/s11883-010-0142-3

Cholesterol Treatment Trialists' Collaboration. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. The Lancet, 376(9753), 1670-1681. Clearfield, M. B." href="http://dx.doi.org/10.1016/S0140-6736(10)61350-5" target="_blank">doi:10.1016/S0140-6736(10)61350-5

Clearfield, M. B. (2010). Altering the pathophysiology of atherosclerosis: The multidimensional role of statins. Journal of the American Osteopathic Association, 110(4 Suppl. 4), 2-6. This material can be found here.

Clearfield, M. B. (2010). Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention. Current Atherosclerosis Reports, 12(1), 8-10. doi:10.1007/s11883-009-0083-x

Clearfield, M. B. (2010). New evidence extending the benefit of treating LDL-C beyond the current guidelines. Current Atherosclerosis Reports, 12(1), 1-4. doi:10.1007/s11883-009-0081-z

Clearfield, M. B. (2010). Rosuvastatin and clinical outcomes in individuals who are not deemed appropriate for baseline statin therapy. Current Atherosclerosis Reports, 12(1), 5-7. doi:10.1007/s11883-009-0082-y

Hiserote, P., & Clearfield, M. B. (2010). Treating risk components of the metabolic syndrome. Journal of the American Osteopathic Association, 110 (3, Suppl. 3), 6-13. This material can be found here.

Satter, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J. M., . . . Clearfield, M. B. (2010). Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. The Lancet, 375(9716), 735-742. doi:10.1016/S0140-6736(09)61965-6

Bray, G. A., Clearfield, M. B., Fintel, D. J., & Nelinson, D. S. (2009). Overweight and obesity: The pathogenesis of cardiometabolic risk. Clinical Cornerstone, 9(4), 30-42. doi: 10.1016/S1098-3597(09)80003-3 This material can be found here.

Cui, Y., Watson, D. J., Girman, C. J., Shapiro, D. R., Gotto, A. M., Hiserote, P., & Clearfield, M. B. (2009). Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). American Journal of Cardiology, 104(6), 829-834. This material can be found here.

Licciardone, J. C., Clearfield, M. B., & Guillory, V. J. (2009). Clinical practice characteristics of osteopathic and allopathic primary care physicians at academic health centers: Results from the National Ambulatory Medical Care Survey. Academic Medicine, 84(6), 744-750. doi: 10.1097/ACM.0b013e3181a424fc This material can be found here.

Shah, B. M., Kemp, R., & Clearfield, M. B. (2009) Using statins to treat healthy patients – are we there yet? Expert Review of Pharmacoeconomics and Outcomes Research, 9(2), 103-105. doi: 10.1586/erp.09.5 This material can be found here.